E-cigarettes may be more effective in helping pregnant smokers quit

May.17.2022
E-cigarettes may be more effective in helping pregnant smokers quit
Pregnant smokers using e-cigarettes are more likely to quit smoking compared to nicotine patch users, according to a study.

Research shows that pregnant smokers are more likely to quit smoking using electronic cigarettes after four weeks than nicotine patches.

 

Researchers have discovered that electronic cigarettes may be equally safe for pregnant women trying to quit smoking as nicotine patches, and may even be a more effective tool.

 

Smoking during pregnancy increases the risk of adverse outcomes such as preterm birth, miscarriage, and low birth weight. However, quitting this habit can be a challenging process.

 

Dr. Francesca Pesola from Queen Mary University of London, the author of this new study, stated that "many pregnant smokers find it difficult to quit smoking using current cessation aids (including nicotine patches) and continue smoking throughout their pregnancy.

 

Although it has been discovered that electronic cigarettes are more effective than nicotine patches in helping people quit smoking, Pesola points out that despite the increasing use of electronic cigarettes by pregnant women, research on their effectiveness or safety is scarce.

 

After attempting to quit smoking for four weeks, 15.4% of individuals who reported using e-cigarettes said that they no longer smoke, compared to only 8.6% of those using nicotine patches.

 

Smoking during pregnancy increases the risk of negative outcomes, including premature birth, miscarriage, and low birth weight for the infant. However, quitting this habit can be a challenging process.

 

Although electronic cigarettes have been shown to be more effective than nicotine patches in helping people quit smoking, Pesola points out that despite an increase in the use of e-cigarettes among pregnant women, there is little research on their effectiveness or safety.

 

Researchers led by Pesola reported in the journal Nature Medicine that they randomly assigned 569 pregnant smokers to use e-cigarettes and 571 pregnant women to use nicotine patches – a nicotine replacement therapy that can already be prescribed during pregnancy. The participants were an average of 15.7 weeks pregnant and smoked 10 cigarettes per day.

 

Only 40% of participants received an electronic cigarette and 23% received a patch, both of which were used for at least four weeks. However, during the study period, those who received electronic cigarettes had higher usage rates and longer usage times.

 

Excluding participants who self-reported not smoking but using nicotine products other than those assigned to them, such as those using nicotine patches along with e-cigarettes, the research team found that those who received e-cigarettes appeared to do better in terms of smoking cessation.

 

After attempting to quit smoking for four weeks, 15.4% of individuals self-reported that they had not smoked, compared to only 8.6% of those who were given patches. At the end of their pregnancies, 19.8% of the e-cigarette group self-reported that they had quit smoking, while only 9.7% of the patch group had done so.

 

Only a small number of participants provided saliva samples to confirm smoking cessation at the end of pregnancy, but once those who used unassigned products were excluded, the research group found that the quit rates among the electronic cigarette group were higher.

 

Additionally, the research team found that the incidence of adverse events was similar between individuals who were given cigarettes and those who were given patches. More importantly, although the average birth weight of infants was similar, low birth weight was more common in the patch group.

 

However, this study has limitations, including low compliance and the use of electronic cigarettes that differ from modern devices.

 

The author further stated that due to the potential risks of nicotine during pregnancy, it is best for pregnant women to quit smoking without using nicotine-containing products.

 

Pesola stated, "We only recommend nicotine use for smokers who wish to quit traditional cigarettes.

 

However, she added, "The risks posed to mothers or infants by using electronic cigarettes are no greater than those posed by nicotine patches. Both are better choices than continuing to smoke throughout the entire course of pregnancy.

 

Source: The Guardian

 

E-cigarettes are equally safe as nicotine patches for pregnant women who smoke and are attempting to quit, according to a report in The Guardian on May 16, 2022.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia Tobacco Retail Permit Takes Effect October 1, Covering Vapes as More Than 3,000 Businesses Apply in September
Virginia's new retail tobacco permit system took effect October 1, requiring sellers of vapes, nicotine products and related devices and accessories to obtain a Retail Tobacco Permit for each business location. Virginia ABC said more than 3,000 businesses applied in September alone, creating a processing backlog. Qualifying applicants that filed before October 1 may temporarily operate under a Letter of Authorization. The new store-level permit also sits alongside Virginia's existing vape product directory, where sales of unlisted liquid nicotine or nicotine vapor products can trigger civil penalties starting at $5,000.
Regulations
Oct.03
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03